8-K current report · filed Sep 28, 2026

Neurocrine Biosciences Inc (NBIX) 8-K Current Report: September 28, 2026

Item 5.02NBIX overview

Short answer

Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CMO transition effective September 28, 2026: Eiry W. Roberts succeeds Sanjay Keswani.

Neurocrine Biosciences Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CMO transition effective September 28, 2026: Eiry W. Roberts succeeds Sanjay Keswani
  • Keswani’s departure was mutually agreed, with severance eligibility under the Executive Severance Plan
  • Roberts’ annual base salary $825,000, with a 2026 target cash bonus equal to 60% of base pay
  • Appointment equity package: approximately $625,000 options, $250,000 RSUs, and $375,000 performance RSUs
  • Leadership change adds execution risk around clinical development and regulatory strategy during the CMO transition

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Neurocrine Biosciences Inc 8-K filings

Get the next NBIX 8-K as it lands

Follow NBIX for push alerts, or ask the research agent what this filing means.